Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL691439 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL5597276 | 0.84 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL5597279 | 0.84 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL5065108 | 0.76 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL5065109 | 0.76 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL691782 | 0.74 | — | — | |
| SCHEMBL4595462 | 0.73 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL5069172 | 0.73 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2POLBHPGDL3MBTL1 | |
| SCHEMBL14031147 | 0.73 | — | — | |
| SCHEMBL14030991 | 0.73 | HPGD (0.36) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2286232-B1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG | 2011-03-24 | — | — | US | disclosed |
| EP-2286232-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009138229-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | CELLZOME AG (DE) | 2009-11-19 | — | — | WO | disclosed |
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| CN-1859912-A | Inhibitors of Akt activity | SMITHKLINE BEECHAM CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070595-A1 | METHODS FOR THE IDENTIFICATION OF PARP INTERACTING MOLECULES AND FOR PURIFICATION OF PARP PROTEINS | PARP3, PARP11, PARP12 | ALDH1A1 1567/4885SMN1; SMN2 4610/4885POLB 169/4885 |
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | ALDH1A1 4166/4885SMN1; SMN2 3299/4885POLB 1321/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | ALDH1A1 2956/4885SMN1; SMN2 3988/4885POLB 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.